These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 18221988)

  • 21. New developments in the pathogenesis of systemic sclerosis.
    Sakkas LI
    Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.
    Cipriani P; Guiducci S; Miniati I; Cinelli M; Urbani S; Marrelli A; Dolo V; Pavan A; Saccardi R; Tyndall A; Giacomelli R; Cerinic MM
    Arthritis Rheum; 2007 Jun; 56(6):1994-2004. PubMed ID: 17530639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B cells in systemic sclerosis: a possible target for therapy.
    Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
    Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
    Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
    Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95.
    Sgonc R; Gruschwitz MS; Boeck G; Sepp N; Gruber J; Wick G
    Arthritis Rheum; 2000 Nov; 43(11):2550-62. PubMed ID: 11083280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events.
    Chizzolini C
    Ann Med; 2007; 39(1):42-53. PubMed ID: 17364450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis.
    Distler JH; Akhmetshina A; Schett G; Distler O
    Rheumatology (Oxford); 2009 Feb; 48(2):98-103. PubMed ID: 18984611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunopathological disturbances in systemic sclerosis].
    Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
    Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma.
    Pannu J; Gardner H; Shearstone JR; Smith E; Trojanowska M
    Arthritis Rheum; 2006 Sep; 54(9):3011-21. PubMed ID: 16947635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vgamma9+ gammadelta T cells in systemic sclerosis patients are numerically and functionally preserved and induce fibroblast apoptosis.
    Bendersky A; Markovits N; Bank I
    Immunobiology; 2010 May; 215(5):380-94. PubMed ID: 19589616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunologic aspects of scleroderma.
    Needleman BW
    Curr Opin Rheumatol; 1992 Dec; 4(6):862-8. PubMed ID: 1457282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts.
    Fineschi S; Cozzi F; Burger D; Dayer JM; Meroni PL; Chizzolini C
    Rheumatology (Oxford); 2007 Dec; 46(12):1779-85. PubMed ID: 17982166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What are the new milestones in the pathogenesis of systemic sclerosis?
    Hunzelmann N; Brinckmann J
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i52-56. PubMed ID: 19995745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
    Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
    Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of IL-13 in systemic sclerosis.
    Fuschiotti P
    Cytokine; 2011 Dec; 56(3):544-9. PubMed ID: 21920770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis.
    Parel Y; Aurrand-Lions M; Scheja A; Dayer JM; Roosnek E; Chizzolini C
    Arthritis Rheum; 2007 Oct; 56(10):3459-67. PubMed ID: 17907151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis.
    Distler JH; Jüngel A; Kowal-Bielecka O; Michel BA; Gay RE; Sprott H; Matucci-Cerinic M; Chilla M; Reich K; Kalden JR; Müller-Ladner U; Lorenz HM; Gay S; Distler O
    Arthritis Rheum; 2005 Mar; 52(3):856-64. PubMed ID: 15751077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of gammadelta T cell supernatant on human skin fibroblast proliferation and collagen production--possible role of transforming growth factor-beta and basic fibroblast growth factor.
    Ohtsuka T
    Int J Dermatol; 2008 Nov; 47(11):1135-40. PubMed ID: 18986443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.
    Sakkas LI; Chikanza IC; Platsoucas CD
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):679-85. PubMed ID: 17133253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients.
    Hénault J; Robitaille G; Senécal JL; Raymond Y
    Arthritis Rheum; 2006 Mar; 54(3):963-73. PubMed ID: 16508979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.